- Neuberg becomes the first lab chain of Indian origin to start direct operations in the USA with CLIA certified lab operations
- Unites key collaborators under one umbrella for molecular and genomics based new generation testing
Neuberg Diagnostics, a global laboratory testing group, announced the start of its clinical laboratory operations in North Carolina in the United States of America (USA). The laboratory in North Carolina, known as NCGM, Inc. (Neuberg Centre for Genomic Medicine), will focus on genomic and molecular testing based on new generation sequencing techniques. It also runs an extensive network of labs in India, South Africa, and the UAE as well.
NCGM has introduced COVID-19 molecular testing to detect active SARS CoV-2 virus infections that is of immediate public health priority in North America, along with genome scale testing, such as Exome Sequencing, which is applicable across a variety of Rare Genetic Disease Testing (Inherited Diseases) from Newborn Screening to Oncology to Pediatric Care Setting.
Dr. GSK Velu, Chairman & Managing Director of Neuberg Diagnostics, said, “NCGM, USA will act as the laboratory and hub, aiding our operations in the North America. Through leveraging our collaborative efforts across our organization in India, South Africa, and UAE, and with our external partners, we aim to develop and provide the best-in-class affordable tests. As they are deployed, the accessibility and affordability of the tests will reduce disparity and benefit individuals across the board.”